or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    LLY D -2.77 10.01
    BSX A 1.14 6.19
    ISRG C 0.98 4.53
    DHR C 0.62 3.67
    AMGN A 11.82 3.58
    ZBH D 2.70 3.38
    BMRN F -1.62 3.08
    PODD D 0.58 3.04
    BIIB D 1.87 2.87
    NBIX A 0.63 2.74
    BMY F 0.66 2.53
    MTD D 0.17 2.24
    ABBV D 1.85 2.17
    A C 1.40 1.99
    DXCM D 1.36 1.93
    IDXX F 1.00 1.78
    SWAV A 0.12 1.74
    HUM F -0.14 1.47
    ALGN F 0.46 1.42
    WST F -0.93 1.35
    EXAS F 2.53 1.31
    VEEV D 1.00 1.31
    EW D 0.22 1.18
    ARGX D -1.33 1.00
    GMAB D 7.22 0.74
    ALNY D 1.34 0.67
    RARE D -1.04 0.62
    IRTC C -7.40 0.53
    NTRA A 3.48 0.52
    ILMN F -4.89 0.49
    XENE C 1.74 0.48
    STVN F -1.34 0.47
    DYN D 0.31 0.40
    ITCI C -2.19 0.39
    PCVX D 2.18 0.39

    Represented by ETF Holdings

    Keywords: S&P 500 Medicine Biopharmaceutical Biotechnology Nasdaq 100 Telemedicine Acid Diabetes Telehealth Cancer Clinical Medicine Depressive Disorder Glucose Lab Testing Life Sciences Monoclonal Antibody Schizophrenia Alzheimer's Disease Amyloid Artery
    Industries: Biotechnology Diagnostics & Research Medical Devices Drug Manufacturers - Major Medical Instruments & Supplies Health Care Plans Health Information Services Long-Term Care Facilities

    Recent News for Goldman Sachs Future Health Care Equity ETF & its Holdings

    Date Stock Title
    May 3 AMGN Why Amgen Stock Zoomed Nearly 12% Higher Today
    May 3 LLY Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
    May 3 SWAV ShockWave Medical Q1 2024 Earnings Preview
    May 3 AMGN Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
    May 3 LLY Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
    May 3 LLY Eli Lilly Remains Expensive Here - Minimal Margin Of Safety
    May 3 RARE Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
    May 3 AMGN Analyst unveils Amgen stock price target after weight-loss drug data
    May 3 LLY Analyst unveils Amgen stock price target after weight-loss drug data
    May 3 DHR Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
    May 3 AMGN Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending
    May 3 NBIX Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
    May 3 ALGN Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
    May 3 BSX Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
    May 3 BSX Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
    May 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
    May 3 AMGN Interest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise
    May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
    May 3 HUM Ensign Group (ENSG) Stock Down 2.4% Despite Q1 Earnings Beat
    May 3 AMGN William Blair, Barclays upgrade Amgen following GLP-1 drug update
    Goldman Sachs Future Health Care Equity ETF is an exchange traded fund launched and managed by Goldman Sachs Asset Management, L.P. The fund invests in the public equity markets across the globe. It invests in stocks of companies operating across health care including genomics, precision medicine, technology-enabled procedures, and digital healthcare sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund employs fundamental analysis and quantitative with to create its portfolio. It seeks to benchmark the performance of its portfolio against the MSCI ACWI Health Care Index. The fund employs proprietary research to create its portfolio. Goldman Sachs Future Health Care Equity ETF was formed on November 9, 2021 and is domiciled in the United States.
    Exchange Traded Funds SPDR Synthetic Replication Genomics Goldman Sachs
    Back to the Main GDOC Page...